CJC-1295 Clinical Research

Pharmacokinetic Studies

The foundational CJC-1295 research was published by Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism. This study demonstrated that a single subcutaneous injection of CJC-1295 (with DAC) produced dose-dependent increases in GH and IGF-1 levels that remained elevated for 6-14 days .

Key findings from this trial:

• Mean IGF-1 levels increased by 1.5 to 3-fold above baseline
• GH pulsatility was preserved (GH was released in natural pulses, not a flat elevation)
• The effect was dose-dependent with a clear dose-response relationship
• Repeated weekly dosing for 4 weeks showed sustained IGF-1 elevation without tachyphylaxis (loss of effectiveness)

Safety Data

Clinical trials of CJC-1295 reported mild and transient adverse events: injection site reactions (redness, swelling), flushing, headache, and diarrhea. No serious adverse events were attributed to CJC-1295 in published trial data .

Ipamorelin Clinical Research

Selectivity Studies

Raun et al. (1998) published the foundational Ipamorelin research in the European Journal of Endocrinology, demonstrating that Ipamorelin was the first growth hormone secretagogue to show true selectivity for GH release. Unlike earlier secretagogues (GHRP-6, hexarelin), Ipamorelin did not significantly increase ACTH, cortisol, prolactin, or aldosterone at GH-stimulating doses .

Post-Surgical Recovery

A Phase II clinical trial studied Ipamorelin for post-operative ileus (bowel recovery after abdominal surgery). While the primary endpoint results were mixed, the trial confirmed Ipamorelin's safety profile in a surgical population and demonstrated meaningful GH elevation .

Dose-Response

Studies showed Ipamorelin produces dose-dependent GH release with a ceiling effect, meaning higher doses eventually plateau rather than producing excessively high GH levels. This built-in safety mechanism distinguishes it from exogenous GH, where higher doses directly produce proportionally higher levels .

Combined CJC-1295/Ipamorelin Evidence

The combination of CJC-1295 and Ipamorelin is based on pharmacological rationale rather than dedicated combination trials:

• Synergistic mechanism: CJC-1295 (GHRH analog) and Ipamorelin (ghrelin receptor agonist) act on different pituitary receptors. Research on GHRH + GHRP combinations consistently shows synergistic GH release exceeding the sum of either peptide alone
• Clinical practice data: Thousands of patients have received CJC-1295/Ipamorelin through compounding pharmacies and anti-aging clinics, with consistent reporting of improved sleep, body composition, and well-being
• IGF-1 monitoring data: Physician-reported data shows predictable IGF-1 responses to CJC-1295/Ipamorelin dosing, consistent with the individual peptide research

Research Limitations

It is important to understand the current evidence gaps:

• No large-scale randomized controlled trial has studied the specific CJC-1295/Ipamorelin combination
• Long-term safety data (beyond 12 months) from controlled trials is limited
• Most clinical benefits are extrapolated from GH replacement therapy research rather than CJC-1295/Ipamorelin-specific trials
• Publication bias may exist, as negative or neutral results are less likely to be published

Frequently Asked Questions

Is CJC-1295/Ipamorelin FDA-approved?

No. Neither CJC-1295 nor Ipamorelin is FDA-approved for any indication. They are prescribed off-label by physicians and compounded by licensed pharmacies under the physician-patient relationship.

How does the evidence compare to other peptides?

CJC-1295 and Ipamorelin each have more human clinical data than many other peptides used in anti-aging medicine (such as BPC-157, which has extensive preclinical but limited human trial data). The evidence base is moderate: stronger than most peptides, but less robust than FDA-approved hormones like recombinant GH.

Are new studies being conducted?

Research on GH secretagogues continues, though pharmaceutical interest has shifted toward newer compounds. The growing clinical use of CJC-1295/Ipamorelin may generate observational data that further clarifies long-term outcomes.